Method for treating parkinson's disease with a botulinum toxin

• US 6,306,403 B1
• Filed: 06/14/2000
• Issued: 10/23/2001
• Est. Priority Date: 06/14/2000
• Status: Expired due to Fees

• Current Assignee: Allergan Sales LLC (Abbvie Incorporated)
• Original Assignee: Allergan Sales LLC (Abbvie Incorporated)
• Inventors: Donovan, Stephen
• Primary Examiner(s): Saoud, Christine J.
• Assistant Examiner(s): Chernyshev, Olga N.
• Application Number:
  US09/596,306
• Time in Patent Office: 496 Days
• Field of Search: 424/239.1, 424/236.1, 424/197.11, 424/234.1, 514/937, 514/944, 514/2
• US Class Current: 424/239.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 21/02 Muscle relaxants, e.g. for tetanus or cramps
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods for treating a movement disorder by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.

Claims

1. A method for temporary reduction of a dyskinesia of Parkinson'"'"'s disease, the method comprising the step of intracranial administration of a botulinum toxin into a globus palladius or into a ventrolateral thalamus, thereby reducing a dyskinesia of Parkinson'"'"'s disease.

2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.

3. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.

4. The method of claim 1, wherein the botulinum toxin is administered in an amount of between about 10⁻

3 U/kg and 10 U/kg.

5. The method of claim 1, wherein the reduction of a dyskinesia of Parkinson'"'"'s disease persists for between about 1 month and about 5 years.

6. The method of claim 1, wherein the botulinum toxin is a modified botulinum toxin.

7. The method of claim 6, wherein the modified botulinum toxin has at least one of its amino acids deleted, modified or replaced, as compared to a native botulinum toxin.

8. The method of claim 6, wherein the modified botulinum toxin is a recombinant produced botulinum toxin or a derivative or fragment thereof.

9. The method of claim 1, wherein the intracranial administration step comprises implantation of a controlled release botulinum toxin system.

10. A method for temporary reduction of a dyskinesia of Parkinson'"'"'s disease, the method comprising the step of intracranial administration of a therapeutically effective amount of a botulinum toxin type A into the globus palladius or into the ventrolateral thalamus, thereby reducing a dyskinesia of Parkinson'"'"'s disease.

11. The method of claim 10, wherein the reduction of a dyskinesia persists for between about 1 month and about 5 years.

12. A method for reducing a dyskinesia of Parkinson'"'"'s disease, the method comprising the step of intracranial administration of a botulinum toxin into a globus palladius nucleus or into a ventrolateral thalamus nucleus of a patient, thereby reducing a dyskinesia of the patient for a period of time of between about 1 month and about 5 years.

13. The method of claim 12, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.

14. A method for temporary reduction of a tremor of Parkinson'"'"'s disease, the method comprising the step of intracranial administration of a botulinum toxin into a globus palladius or into a ventrolateral thalamus, thereby reducing a tremor of Parkinson'"'"'s disease.

15. The method of claim 14, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F and G.

16. The method of claim 14, wherein the botulinum toxin is botulinum toxin type A.

17. The method of claim 14, wherein the reduction of a tremor of Parkinson'"'"'s disease persists for between about 1 month and about 5 years.